NOW ENROLLING
TRIALS IN LUNG CANCER

Atezolizumab
TRIAL OF IMMUNOTHERAPY-BASED COMBINATION THERAPY IN PATIENTS WITH METASTATIC NSCLC

Ph I/II • NCT03337698

MORPHEUS-Lung

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

• Patients with metastatic NSCLC. Includes 1L cohort of patients who have not received any systemic therapy and 2L cohort of patients who progressed during or after receiving a platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor treatment (N=305)

TRIAL OF NEOADJUVANT AND ADJUVANT ATEZOLIZUMAB IN PATIENTS WITH RESECTABLE NSCLC

Ph III • NCT03456063

IMpower030

A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non–Small Cell Lung Cancer

• Patients with resectable Stage II, IIIA, or select IIIB NSCLC of squamous or non-squamous histology (N=374)
NOW ENROLLING

**Entrectinib**
TRIAL OF MULTIPLE TARGETED THERAPIES, INCLUDING ENTRECTINIB, IN PATIENTS WITH NSCLC

Ph II/III • NCT03178552

B-FAST
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

- Patients with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or high TMB as identified by NGS ctDNA assays (N=660)

**iNeST**
TRIAL OF iNeST AND ATEZOLIZUMAB IN PATIENTS WITH SOLID TUMORS, INCLUDING NSCLC*

Ph Ia/Ib • NCT03289962

A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors

- Patients with incurable, locally advanced/metastatic solid tumors, including advanced NSCLC a) not previously treated with anti–PD-L1/PD-1 and/or anti–CTLA-4, or b) previously treated with anti–PD-L1/PD-1 with or without anti–CTLA-4 (N=770)

*In collaboration with BioNTech SE.

Information is consistent with ClinicalTrials.gov as of May 1, 2020.

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

1L=first line; 2L=second line; ALK=anaplastic lymphoma kinase; CIT=cancer immunotherapy; CPI=checkpoint inhibitor; CTLA-4=cytotoxic T-lymphocyte-associated protein 4; ctDNA=circulating-tumor DNA; EGFR=epidermal growth factor receptor; ES-SCLC=extensive-stage small cell lung cancer; iNeST=Individualized Neoantigen Specific Immunotherapy; NGS=next-generation sequencing; NSCLC=non-small cell lung cancer; PD-1=programmed cell death protein 1; PD-L1=programmed death-ligand 1; Ph=phase; SCLC=small cell lung cancer; TIM3=T-cell immunoglobulin mucin-3; TMB=tumor mutational burden.
NOW ENROLLING

PD-1 x TIM3
TRIAL OF PD-1 AND TIM3 BISPECIFIC ANTIBODY IN PATIENTS WITH SOLID TUMORS, INCLUDING NSCLC AND SCLC

Ph I • NCT03708328

An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors

• Patients with advanced/metastatic solid tumors, including a) NSCLC previously treated with PD-L1/PD-1 inhibitors and platinum-based chemotherapy, b) untreated, CIT-naïve NSCLC, and c) CPI-naïve SCLC (N=300)

Tiragolumab
TRIAL OF 1L TIRAGOLUMAB AND ATEZOLIZUMAB IN PATIENTS WITH NSCLC

Ph III • NCT04294810

SKYSCRAPER-01

A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

• Patients with previously untreated locally advanced, unresectable or metastatic PD-L1–selected NSCLC, with no EGFR mutation or ALK translocation (N=500)

Information is consistent with ClinicalTrials.gov as of May 1, 2020.
These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.
NOW ENROLLING

TRIAL OF 1L TIRAGOLUMAB AND ATEZOLIZUMAB IN PATIENTS WITH ES-SCLC

Ph III • NCT04256421
SKYSCRAPER-02

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

• Patients with chemotherapy-naive extensive-stage SCLC (N=400)

Find out if your patients with lung cancer are eligible to enroll

VISIT
ClinicalTrials.gov

PHONE
Genentech Trial Information Support Line:
1-888-662-6728 (US only)

EMAIL
global-roche-genentech-trials@gene.com

Information is consistent with ClinicalTrials.gov as of May 1, 2020.
These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

1L=first line; 2L=second line; ALK=anaplastic lymphoma kinase; CIT=cancer immunotherapy; CPI=checkpoint inhibitor; CTLA-4=cytotoxic T-lymphocyte-associated protein 4; ctDNA=circulating-tumor DNA; EGFR=epidermal growth factor receptor; ES-SCLC=extensive-stage small cell lung cancer; iNeST=Individualized Neoantigen Specific Immunotherapy; NGS=next-generation sequencing; NSCLC=non-small cell lung cancer; PD-1=programmed death protein 1; PD-L1=programmed death-ligand 1; Ph=phase; SCLC=small cell lung cancer; TIM3=T-cell immunoglobulin mucin-3; TMB=tumor mutational burden.